The latest results from the third International Stroke Trial (IST-3) suggest that the drug has the potential to cut costs by reducing the demand for long-term care. Treatment for acute ischemic stroke ...

In 2001, the US Food and Drug Administration approved recombinant tissue plasminogen activator (alteplase, Cathflo Activase) to reestablish patency of central catheters occluded, presumably, by a ...

The thrombolytic drug alteplase, despite recent concerns, is safe and effective in routine clinical use when used within 3 hours of stroke onset, according to an observational study published in this ...

Recombinant tissue plasminogen activator (rtPA; alteplase) is the only thrombolytic agent licensed for the treatment of patients with acute ischemic stroke. One of the conditions of licensing in the ...